The FDA has approved a new heart failure medication. Amgen's Corlanor (ivanbradine). It's the first drug of its kind to be approved in over ten years. The manufacturer Novartis also has a heart failure medication in the process of approval, that should be available this summer according to the Associated Press.
According to Dr. Mary Norine Walsh, a vice president at the American College of Cardiology and head of the heart treatment and cardiac transplantation at St Vincent Heart Center in Indianapolis, the drugs target different types of patients and their mechanism of action is different.
"The No. 1 thing is going to be how expensive" the drugs are and whether insurers set high co-pays -- if they even cover them," Walsh said. "When we say to a patient that we'll replace your medicine that you can get for $4 (as a generic), nonmedical decision-making will come into play."
The list price of Corlanor will be around $375 per month, without insurance. Novartis has yet to set a price for their drug.
Source: Associated Press